MC1R comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2026-06-07. Numbers and descriptions here follow the published literature rather than marketing material.
Melanotan-2, also written Melanotan II, is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone. Its sequence is Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH2, and the lactam bridge between the aspartate and lysine side chains constrains the peptide into a ring. This structural change increases receptor affinity and metabolic stability relative to the native hormone. The compound was created in the 1980s as a research tool for studying pigmentation biology.
Melanocytes are the pigment-producing cells of the skin, and they carry melanocortin-1 receptors on their surface. When the receptor is activated, cyclic adenosine monophosphate rises inside the cell and raises the activity of enzymes such as tyrosinase, which increases melanin output. Melanotan-2 binds melanocortin-1 receptors in vitro and in animal models, and this binding is generally described as the basis for the tanning effect. Other receptors account for different effects: melanocortin-4 receptors contribute to appetite and erectile signalling, while melanocortin-3 and melanocortin-5 receptors contribute to energy balance and exocrine function.
Activity is attributed to agonism at melanocortin receptors, particularly MC1R and MC4R. Activation of MC1R on melanocytes increases melanin synthesis, which underlies the reported tanning effect. MC4R engagement in the central nervous system is linked to appetite suppression and to effects on sexual arousal reported in early clinical studies. Those studies were small and were not designed to establish efficacy or long-term safety. Receptor selectivity among the melanocortin subtypes is not absolute, which complicates attribution of any effect to a single pathway.
Regulatory treatment varies between countries. Several national medicines agencies have classified the peptide as unapproved, and customs authorities in some jurisdictions seize shipments on that basis. A few jurisdictions channel supply through prescription-only frameworks that do not list the substance by name. Because the material circulates mainly through online vendors, composition and purity are rarely verified before sale. Surveys of unapproved peptide products have reported labels that did not match measured content in a substantial fraction of samples.
| Property | Value | Notes |
|---|---|---|
| Compound class | Synthetic cyclic heptapeptide | Alpha-MSH analogue containing a D-phenylalanine residue |
| Molecular formula | C50H69N15O9 | Average molecular mass approximately 1024.2 g/mol |
| Appearance | White to off-white lyophilised powder | Normally supplied as a freeze-dried solid in a sealed vial |
| Solubility | Freely soluble in water and polar solvents | Dissolves readily in aqueous buffers and in alcohol-water mixtures |
| Receptor targets | MC1R, MC3R, MC4R, MC5R | Acts as a non-selective melanocortin receptor agonist |
Research interest has centred on photoprotection and pigmentation, with a smaller body of work on appetite and sexual function. Published human data remain limited to small, frequently uncontrolled studies, and the compound has never received marketing approval from a national medicines regulator. Most laboratory work treats it as a pharmacological tool for probing melanocortin signalling in cell culture or animal models. Whether pigmentation changes observed in people translate into measurable protection against ultraviolet-induced DNA damage remains an open question.
Melanotan-2 is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone, the naturally occurring peptide involved in pigmentation signalling. Its sequence is conventionally written as Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH2, with a lactam bridge joining the aspartate side chain to the lysine side chain. The empirical formula is C50H69N15O9 and the monoisotopic mass lies near 1023.5 daltons. N-terminal acetylation and the D-configured phenylalanine both increase resistance to enzymatic breakdown compared with the parent hormone.
Pharmacologically, melanotan-2 behaves as a non-selective agonist across the melanocortin receptor family. Binding at MC1R on dermal melanocytes promotes eumelanin synthesis, which underlies the tanning response described in early human work. Activity at the centrally expressed MC4R receptor is associated with reported effects on appetite and erectile function. Because the peptide does not discriminate strongly among receptor subtypes, attributing any single observed effect to one receptor pathway is generally not possible without selective antagonists or receptor knockout models.
Two structural changes distinguish the synthetic peptide from the natural hormone. A norleucine residue replaces methionine at one position, and a D-configured phenylalanine replaces the natural L-form at another. Both substitutions slow enzymatic breakdown, which extends the molecule's persistence relative to the parent hormone. The lactam bridge further constrains the backbone into a stable conformation. These features are standard design strategies in peptide chemistry and are not unique to this compound; they appear across many research peptides built for improved stability.
The compound was developed in the late 1980s and early 1990s by academic researchers investigating melanocortin signaling and pigmentation. Early work explored whether synthetic analogs could reproduce effects of the natural hormone under controlled conditions. The molecule never advanced through the full regulatory pathway required for approval as a medicine. From the mid-2000s onward it appeared in unregulated consumer markets, often distributed through informal channels. That gap between research origins and commercial availability shapes how the compound is discussed today.
An additional 35 primordial nuclides (to a total of 286 primordial nuclides), are radioactive with known half-lives, but have half-lives longer than 100 million years, allowing them to exist from the beginning of the Solar System. See list of nuclides for details. All the known stable nuclides occur naturally on Earth; the other naturally occurring nuclides are radioactive but occur on Earth due to their relatively long half-lives, or else due to other means of ongoing natural production. These include the afore-mentioned cosmogenic nuclides, the nucleogenic nuclides, and any radiogenic nuclides formed by ongoing decay of a primordial radioactive nuclide, such as radon and radium from uranium. An additional ~3000 radioactive nuclides not found in nature have been created in nuclear reactors and in particle accelerators. Many short-lived nuclides not found naturally on Earth have also been observed by spectroscopic analysis, being naturally created in stars or supernovae. An example is aluminium-26, which is not naturally found on Earth but is found in abundance on an astronomical scale. The tabulated atomic masses of elements are averages that account for the presence of multiple isotopes with different masses. Before the discovery of isotopes, empirically determined noninteger values of relative atomic mass confounded scientists. For example, a sample of chlorine contains 75.8% chlorine-35 and 24.2% chlorine-37, giving an average atomic mass of 35.5 daltons.
=== Discontinuation === The British National Formulary recommends a gradual withdrawal when discontinuing antipsychotics to avoid acute withdrawal syndrome or rapid relapse. Symptoms of withdrawal commonly include nausea, vomiting, and loss of appetite. Other symptoms may include restlessness, increased sweating, and trouble sleeping. Less commonly, there may be a feeling of the world spinning, numbness, or muscle pains. Symptoms generally resolve after a short period of time. There is tentative evidence that discontinuation of antipsychotics can result in psychosis. It may also result in reoccurrence of the condition that is being treated. Rarely, tardive dyskinesia can occur when the medication is stopped.
=== Spider and other silks === Spider silk, particularly the dragline silk of orb-weaving spiders, is both very strong and highly extensible, which places it among the toughest natural fibres known. The principal constraint is supply. Spiders are territorial and cannibalistic and cannot be farmed as silkworms are, so natural spider silk remains scarce. Instead, spider-silk proteins are produced by genetic engineering and expressed in bacteria, yeast or other hosts. Silks from wild silkmoths such as Antheraea species, and from other insects, have also been examined; they differ in amino acid sequence and in how they interact with cells.
== History == The chain was founded in Eugene by Ron Fraedrick (1928–2015), who opened the first restaurant near his alma mater, the University of Oregon, at 13th Avenue and High Street in January 1960. In 1962, the first Taco Time franchise opened in White Center, Washington. In the 1970s, the company expanded to 48 restaurants in seven Western states. In 1978, the company franchised its first international restaurant in Lethbridge, Alberta, Canada. In 1979, Taco Time Northwest became a licensee with the rights to franchise and operate the Taco Time concept independently. Taco Time Northwest's operating region includes western Washington from Longview to the Canada–United States border and the eastern Washington cities of Wenatchee and Moses Lake. In 1984, food at a location in The Dalles was allegedly poisoned by members of the Rajneesh movement in a bioterror attack. Taco Time has since expanded, now holding more than 300 franchises in the United States and Canada. They previously had locations in Kuwait, Greece, and Netherlands Antilles (Curaçao) which seem to have closed. In 2003, the company was bought by Kahala Brands of Scottsdale, Arizona.
Sources: en.wikipedia.org
Arrestins are elongated molecules, in which several intra-molecular interactions hold the relative orientation of the two domains. Unstimulated cell arrestins are localized in the cytoplasm in a basal inactive conformation. Active phosphorylated GPCRs recruit arrestin to the plasma membrane. Receptor binding induces a global conformational change that involves the movement of the two arrestin domains and the release of its C-terminal tail that contains clathrin and AP2 binding sites. Increased accessibility of these sites in receptor-bound arrestin targets the arrestin-receptor complex to the coated pit. Arrestins also bind microtubules (part of the cellular skeleton), where they assume yet another conformation, different from both free and receptor-bound form. Microtubule-bound arrestins recruit certain proteins to the cytoskeleton, which affects their activity and/or redirects it to microtubule-associated proteins. Arrestins shuttle between cell nucleus and cytoplasm. Their nuclear functions are not fully understood, but it was shown that all four mammalian arrestin subtypes remove some of their partners, such as protein kinase JNK3 or the ubiquitin ligase Mdm2, from the nucleus. Arrestins also modify gene expression by enhancing transcription of certain genes.
Absorption is the journey of a drug travelling from the site of administration to the site of action. The drug travels by some route of administration (oral, topical-dermal, etc.) in a chosen dosage form (e.g., tablets, capsules, or in solution). Absorption by some other routes, such as intravenous therapy, intramuscular injection, enteral nutrition, is even more straightforward and there is less variability in absorption and bioavailability is often near 100%. Intravascular administration does not involve absorption, and there is no loss of drug. The fastest route of absorption is inhalation. Absorption is a primary focus in drug development and medicinal chemistry, since a drug must be absorbed before any medicinal effects can occur. Moreover, the drug's pharmacokinetic profile can be easily and significantly changed by adjusting factors that affect absorption.
Bruce Glick grew up in Pittsburgh, Pennsylvania and was interested in birds as a child. His father, Peter Glick, was the Secretary of Labor for Pennsylvania. Glick served in World War II. He went to Rutgers University and studied birds majoring in poultry science, graduating in 1951. In 1950 he married Kay McCall. He received an M.S. degree from the University of Massachusetts in genetics in 1952 and attended Ohio State University as a Ph.D. student, graduating with a PhD in physiology in 1955. While there, he worked on determining the purpose of the Bursa of Fabricius, a gland that he was able to remove from a goose without any apparent effect. A fellow graduate student, Timothy Chang, worked with Glick's geese in a different study, and noticed that the birds without the Bursa of Fabricius did not produce expected antibodies. Glick and Chang wrote up the results of this study and were unable to get it published in Science, so it was published in Poultry Science in 1956. Their publication, considered a landmark paper, is one of the most cited works from Poultry Science.
Actinium is a chemical element; it has symbol Ac and atomic number 89. It was discovered by Friedrich Oskar Giesel in 1902, who gave it the name emanium; the element got its name by being wrongly identified with a substance André-Louis Debierne found in 1899 and called actinium. The actinide series, a set of 15 elements between actinium and lawrencium in the periodic table, is named after actinium. Together with polonium, radium, and radon, actinium was one of the first non-primordial radioactive elements to be discovered. A soft, silvery-white radioactive metal, actinium reacts rapidly with oxygen and moisture in air, forming a white coating of actinium oxide that prevents further oxidation. As with most lanthanides and many actinides, actinium assumes oxidation state +3 in nearly all its chemical compounds. Actinium is found only in traces in uranium and thorium ores as the isotope 227Ac, which decays with a half-life of 21.772 years, predominantly emitting beta and sometimes alpha particles, and 228Ac, which is beta active with a half-life of 6.15 hours. One tonne of natural uranium in ore contains about 0.2 milligrams of actinium-227, and one tonne of thorium contains about 5 nanograms of actinium-228. The close similarity of physical and chemical properties of actinium and lanthanum makes the separation of actinium from the ore impractical. Instead, the element is prepared, in milligram amounts, by the neutron irradiation of 226Ra in a nuclear reactor. Owing to its scarcity, high price, and radioactivity, actinium has no significant industrial use.
Psychiatric treatments have changed over the past several decades. In the past, psychiatric patients were often hospitalized for six months or more, with some cases involving hospitalization for many years. Average inpatient psychiatric treatment stay has decreased significantly since the 1960s, a trend known as deinstitutionalization. Today in most countries, people receiving psychiatric treatment are more likely to be seen as outpatients. If hospitalization is required, the average hospital stay is around one to two weeks, with only a small number receiving long-term hospitalization. However, in Japan psychiatric hospitals continue to keep patients for long periods, sometimes even keeping them in physical restraints, strapped to their beds for periods of weeks or months. Psychiatric inpatients are people admitted to a hospital or clinic to receive psychiatric care. Some are admitted involuntarily, perhaps committed to a secure hospital, or in some jurisdictions to a facility within the prison system. In many countries including the United States and Canada, the criteria for involuntary admission vary with local jurisdiction. They may be as broad as having a mental health condition, or as narrow as being an immediate danger to themselves or others. Bed availability is often the real determinant of admission decisions to hard pressed public facilities. People may be admitted voluntarily if the treating doctor considers that safety is not compromised by this less restrictive option.
Sources: en.wikipedia.org
No. It is a laboratory-made peptide, while the natural hormone is alpha-melanocyte-stimulating hormone, a longer peptide produced by the pituitary gland and by skin cells. Melanotan-2 mimics only a short active region of that hormone and contains non-natural residues such as D-phenylalanine.
No approved regulatory indication exists in major markets. An approval exists for a different peptide, afamelanotide, which is used for a rare photosensitivity disorder called erythropoietic protoporphyria. Melanotan-2 itself remains a research compound with no cleared clinical role.
Melanocortin-1 receptors on melanocytes are the receptor most closely linked to pigment production. The peptide is not selective, however, and also activates melanocortin-3, melanocortin-4, and melanocortin-5 receptors. That lack of selectivity is the usual explanation offered for both its range of observed effects and its off-target effects.
No. No major regulatory agency has granted a marketing authorisation for melanotan II as a medicine. Products sold under this name are generally presented as laboratory reagents and are not subject to the batch-release testing applied to approved drugs.